This article is available to subscribers. Subscribe now. Already have an account? Sign in

Medical IntelligenceDrug TherapyFree PreviewArchive

Dobutamine: A New Synthetic Cardioactive Sympathetic Amine

List of authors.
  • Edmund H. Sonnenblick, M.D.,
  • William H. Frishman, M.D.,
  • and Thierry H. LeJemtel, M.D.

Dobutamine* is a new, synthetic, intravenously administered catecholamine that acts directly to increase myocardial contractility without inducing marked tachycardia or greatly changing peripheral arterial resistance.1 These features make it useful for treating acute cardiac failure characterized by low cardiac output and elevated diastolic filling pressures, and in July, 1978, it was approved for clinical use in this country.Norepinephrine is the endogenous catecholamine that is synthesized and stored in granules in adrenergic nerve endings in the myocardium. When sympathetic nerves to the heart are activated, norepinephrine is released from its stores and stimulates specific sites on the myocardial cell surface, . . .

Funding and Disclosures

Supported in part by a training grant (HL 07071–02) from the U.S. Public Health Service.

* Dobutamine hydrochloride (Dobutrex, Lilly).

Author Affiliations

From the Division of Cardiology, Department of Medicine, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY 10461, where reprint requests should be addressed to Dr. Sonnenblick.

Print Subscriber? Activate your online access.